
Glaukos Corp., a global leader in ophthalmic pharmaceuticals and medical technologies, kicked off a project to open a new, state-of-the-art research, development and manufacturing facility in Huntsville.
The project, located on 25 acres in Cummings Research Park, will feature a 200,000-square-foot advanced facility dedicated to developing novel therapies for glaucoma, corneal disorders and retinal diseases.
Click here to read the rest of the story.